scPharmaceuticals 배당금 및 환매

배당금 기준 확인 0/6

scPharmaceuticals 배당금을 지급한 기록이 없습니다.

주요 정보

n/a

배당 수익률

-32.3%

환매 수익률

총 주주 수익률	-32.3%
미래 배당 수익률	n/a
배당금 성장	n/a
다음 배당금 지급일	n/a
전 배당일	n/a
주당 배당금	n/a
지급 비율	n/a

최근 배당금 및 환매 업데이트

업데이트 없음

Recent updates

scPharmaceuticals Inc. (NASDAQ:SCPH) Shares Slammed 26% But Getting In Cheap Might Be Difficult Regardless

Nov 19

Downgrade: Here's How Analysts See scPharmaceuticals Inc. (NASDAQ:SCPH) Performing In The Near Term

Nov 18

Is scPharmaceuticals (NASDAQ:SCPH) Using Too Much Debt?

Jun 27

scPharmaceuticals Inc. (NASDAQ:SCPH) Stocks Shoot Up 26% But Its P/S Still Looks Reasonable

Jun 27

The scPharmaceuticals Inc. (NASDAQ:SCPH) Full-Year Results Are Out And Analysts Have Published New Forecasts

Mar 16

Is scPharmaceuticals (NASDAQ:SCPH) Using Debt Sensibly?

Nov 25

scPharmaceuticals: Furoscix Approval A Potential Paradigm Shift For Heart Failure Patients

Oct 20

Here's What scPharmaceuticals Inc.'s (NASDAQ:SCPH) Shareholder Ownership Structure Looks Like

Mar 09

How Many scPharmaceuticals Inc. (NASDAQ:SCPH) Shares Do Institutions Own?

Nov 24

결제의 안정성과 성장

배당금 데이터 가져오기

안정적인 배당: 과거에 SCPH 의 주당 배당금이 안정적이었는지 판단하기에는 데이터가 부족합니다.

배당금 증가: SCPH 의 배당금 지급이 증가했는지 판단하기에는 데이터가 부족합니다.

시장 대비 배당 수익률

scPharmaceuticals 시장 대비 배당 수익률

SCPH 배당 수익률은 시장과 어떻게 비교되나요?
세그먼트	배당 수익률
회사 (SCPH)	n/a
시장 하위 25% (US)	1.4%
시장 상위 25% (US)	4.3%
업계 평균 (Pharmaceuticals)	2.4%
애널리스트 예측 (SCPH) (최대 3년)	n/a

주목할만한 배당금: 회사가 최근 지급을 보고하지 않았기 때문에 하위 25%의 배당금 지급자에 대해 SCPH 의 배당 수익률을 평가할 수 없습니다.

고배당: 회사가 최근 지급을 보고하지 않았기 때문에 배당금 지급자의 상위 25%에 대해 SCPH 의 배당 수익률을 평가할 수 없습니다.

주주에 대한 수익 배당금

수익 보장: 배당금 지급이 수익으로 충당되는지 확인하기 위해 SCPH 의 지급 비율을 계산하기에는 데이터가 부족합니다.

주주에 대한 현금 배당금

현금 흐름 범위: SCPH 에서 지급을 보고하지 않았기 때문에 배당 지속 가능성을 계산할 수 없습니다.

scPharmaceuticals 배당금 및 환매

배당금 기준 확인 0/6

주요 정보

최근 배당금 및 환매 업데이트

Recent updates

Consensus EPS estimates fall by 42%

scPharmaceuticals Inc. (NASDAQ:SCPH) Shares Slammed 26% But Getting In Cheap Might Be Difficult Regardless

Downgrade: Here's How Analysts See scPharmaceuticals Inc. (NASDAQ:SCPH) Performing In The Near Term

Third quarter 2024 earnings: EPS and revenues miss analyst expectations

scPharmaceuticals Inc. to Report Q3, 2024 Results on Nov 13, 2024

Second quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

New minor risk - Shareholder dilution

scPharmaceuticals Inc. has completed a Follow-on Equity Offering in the amount of $49.9995 million.

scPharmaceuticals Inc. has filed a Follow-on Equity Offering.

scPharmaceuticals Announces Filing Acceptance of Supplemental New Drug Application (sNDA) Seeking to Expand FUROSCIX Indication to Include Chronic Kidney Disease

Is scPharmaceuticals (NASDAQ:SCPH) Using Too Much Debt?

scPharmaceuticals Inc. (NASDAQ:SCPH) Stocks Shoot Up 26% But Its P/S Still Looks Reasonable

New minor risk - Share price stability

New minor risk - Financial position

scPharmaceuticals Inc. to Report Q1, 2024 Results on May 14, 2024

scPharmaceuticals Inc., Annual General Meeting, Jun 11, 2024

scPharmaceuticals Inc. Announces First Participant Enrolled in Pivotal Pharmacokinetic Study of Furoscix Auto-Injector (Furosemide 80Mg/Ml) Injection

Consensus EPS estimates fall by 20%, revenue upgraded

The scPharmaceuticals Inc. (NASDAQ:SCPH) Full-Year Results Are Out And Analysts Have Published New Forecasts

scPharmaceuticals Inc. has filed a Follow-on Equity Offering in the amount of $50 million.

scPharmaceuticals Inc. to Report Q4, 2023 Results on Mar 13, 2024

scPharmaceuticals Inc. Provides Revenue Guidance for the Full Year 2023

Forecast to breakeven in 2026

Is scPharmaceuticals (NASDAQ:SCPH) Using Debt Sensibly?

scPharmaceuticals Inc. to Report Q3, 2023 Results on Nov 08, 2023

Scpharmaceuticals Announces Positive Feedback from Two Fda Meetings on Key Long-Term Growth Initiatives

Forecast to breakeven in 2025

scPharmaceuticals Inc. to Report Q2, 2023 Results on Aug 10, 2023

scPharmaceuticals Announces Positive Type C Meeting Feedback from FDA on Potential Heart Failure Class IV Indication Expansion

Insufficient new directors

Forecast to breakeven in 2025

Forecast to breakeven in 2025

No longer forecast to breakeven

scPharmaceuticals Provides FUROSCIX® (furosemide injection) Commercial Update

Forecast to breakeven in 2025

scPharmaceuticals Inc. Announces Appointment of Rachael Nokes as Chief Financial Officer

scPharmaceuticals Inc. has completed a Follow-on Equity Offering in the amount of $50.003345 million.

scPharmaceuticals Inc. has completed a Follow-on Equity Offering in the amount of $50.003345 million.

Price target increased to US$14.25

scPharmaceuticals Inc. Revises Earnings Guidance for the Year 2022

scPharmaceuticals Inc. to Report Q3, 2022 Results on Nov 09, 2022

scPharmaceuticals: Furoscix Approval A Potential Paradigm Shift For Heart Failure Patients

Consensus forecasts updated

Price target increased to US$13.00

scPharmaceuticals Inc. announced that it expects to receive $100 million in funding from Oaktree Capital Management, L.P.

FDA approves scPharmaceuticals Furoscix to treat congestion in heart failure

Consensus forecasts updated

scPharmaceuticals Inc. Announces Positive Results from the at Home-HF Phase 2 Pilot Study in Heart Failure

scPharmaceuticals Inc. Provides Earnings Guidance for the Year 2022

scPharmaceuticals Inc. Announces Resubmission of Furoscix® New Drug Application

Consensus forecasts updated

Price target increased to US$13.00

Does scPharmaceuticals (NASDAQ:SCPH) Have A Healthy Balance Sheet?

scPharmaceuticals Inc. Presents Late-breaking FREEDOM-HF Study Data at the Heart Failure Society of America Annual Scientific Meeting 2021

Price target decreased to US$10.67

Is scPharmaceuticals (NASDAQ:SCPH) A Risky Investment?

scPharmaceuticals: We Still See A High Probability Of Success For FUROSCIX

scPharmaceuticals Inc. Provides Earnings Guidance for the Year 2021

scPharmaceuticals Inc. Announces Positive Top-Line Results from FREEDOM-HF Study

scPharmaceuticals Inc. Announces Receipt of Written Minutes from Type C Meeting with the FDA Regarding Development of FUROSCIX®

scPharmaceuticals Inc.(NasdaqGS:SCPH) dropped from Russell 3000E Index

Scpharmaceuticals Inc. Announces Earnings Guidance for 2021

Scpharmaceuticals Inc. Provides Earnings Forecasts for the Year 2021

Here's What scPharmaceuticals Inc.'s (NASDAQ:SCPH) Shareholder Ownership Structure Looks Like

scPharmaceuticals Inc. Appoints William T. Abraham, M.D., to Its Board of Directors

Price target lowered to US$11.00

New 90-day low: US$5.63

Scpharmaceuticals Inc. Announces Resignation of Mason W. Freeman as A Member of the Board and All Committees, Effective as of December 15, 2020

How Many scPharmaceuticals Inc. (NASDAQ:SCPH) Shares Do Institutions Own?

Scpharmaceuticals Inc. Announces Financial Guidance for 2020

결제의 안정성과 성장

시장 대비 배당 수익률

주주에 대한 수익 배당금

주주에 대한 현금 배당금

강력한 배당금 지급 기업 알아보기